News & Media
Learn more about the latest happenings at Otsuka. Select to see US news or read our press releases. You can also stay up to date with our global news in the link below.
![Image](/sites/g/files/qhldwo9046/files/styles/max_325x325/public/2020-11/image-full-bleed-copy%403x.jpg?itok=wwRC_Cyh)
Media Contact:
Senior Director, External Communications,
Otsuka America Pharmaceutical, Inc
(Tokyo, Japan and Princeton, N.J.) – Otsuka Pharmaceutical Co., Ltd. (OPCJ) and its affiliate Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) are pleased to invite investors and media to a November 4 web briefing on in-depth results from the REPRISE phase 3 trial for tolvaptan, a drug candidate for the treatment of patients in the U.S. with autosomal dominant polycystic
Tokyo, Japan and Deerfield, Ill. – Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Lundbeck announce that patient enrollment has been initiated in two global Phase 3 clinical trials to evaluate brexpiprazole for the treatment of patients with manic episodes associated with bipolar I disorder. The Phase 3 trials will evaluate the efficacy and safety of brexpiprazole in patients with bipolar
Eight data presentations supporting treatments for major depressive disorder, bipolar I disorder and schizophrenia to be presented at the upcoming annual Psych Congress (PRINCETON, N.J., & DEERFIELD, Ill.) – Otsuka Pharmaceutical Development & Commercialization, Inc. and Lundbeck U.S. today announced upcoming data presentations reinforcing the long- term safety and efficacy of
First FDA approved, once-monthly, long-acting injectable for the maintenance monotherapy treatment of bipolar I disorder in adults1,2New indication for ABILIFY MAINTENA is based on studies evaluating efficacy and safety in adult patients with bipolar I disorder1 (TOKYO, Japan & VALBY, Denmark, July 28, 2017) – Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S today announced